Concepedia

A Phase II Study of Capecitabine plus Oxaliplatin as First-Line Chemotherapy in Elderly Patients with Advanced Gastric Cancer

Xiao Xiang, Ling Zhang, Feng Qiu, Yu Feng, Zheng Yu Zhan, Feng Miao, Jun Yan, Jian Zhao, Jian Xiong

Chemotherapy · 2012 · 32 citations · 35 references

Abstract

The XELOX regimen with capecitabine at a lower dose of 850 mg/m(2) is active, fairly tolerable and conveniently delivered as first-line chemotherapy for elderly AGC patients.

References

35

Global cancer statistics

Ahmedin Jemal, Freddie Bray · CA A Cancer Journal for Clinicians · 2011 · 55K citations · Full text

Global Cancer Statistics, 2002

Donald Maxwell Parkin, Freddie Bray, Jacques Ferlay et al. · CA A Cancer Journal for Clinicians · 2005 · 18.4K citations · Full text

Epidemiology Of Cancer, Worldwide Incidence, Cancer Registration +16

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer et al. · JNCI Journal of the National Cancer Institute · 2000 · 15.7K citations

World Health Organization, Solid Tumors, Cancer Management +17

Optimal two-stage designs for phase II clinical trials

Richard Simon · Controlled Clinical Trials · 1989 · 3.6K citations

Clinical Trial Management, Clinical Trials, Randomized Controlled Trial +6

Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer

David Cunningham, Naureen Starling, Sheela Rao et al. · New England Journal of Medicine · 2008 · 2.3K citations